CROHN’S DISEASE - DR. REMO PANACCIONE

SATURDAY, MAY 6

12:00 – 2:00 PM
SA1878. RECENT ANTI-TNF EXPOSURE PREDICTS LOWER VEDOLIZUMAB TROUGHS CONCENTRATIONS IN PATIENTS WITH CROHN DISEASE

MONDAY, MAY 8

10:15 – 10:30 AM
616. LONG-TERM SAFETY OF ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE: FINAL DATA FROM PYRAMID REGISTRY

2:00 – 2:15 PM
1076. CORRELATION OF CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH ACTIVE CROHN’S DISEASE TREATED WITH MONGERSEN (GED-0301)

5:16 – 5:30 PM
718. SUPERIOR ENDOSCOPIC AND DEEP REMISSION OUTCOMES IN ADULTS WITH MODERATE TO SEVERE CROHN’S DISEASE MANAGED WITH TREAT TO TARGET APPROACH VERSUS CLINICAL SYMPTOMS: DATA FROM CALM

TUESDAY, MAY 9

10:00 – 10:15 AM
874H. SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM CELEST

11:00 – 11:15 AM
8741. EFFICACY AND SAFETY OF OPEN-LABEL MAINTENANCE THERAPY WITH SUBCUTANEOUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE

ULCERATIVE COLITIS - DR. VIPUL JAIRATH

SATURDAY, MAY 6

12:00 – 2:00 PM
SA1877. SEVERELY ACTIVE ULCERATIVE COLITIS IS ASSOCIATED WITH HIGH BASELINE INFliximab CLEARANCE, REDUCED SERUM HALF-LIFE AND WORSE ENDOSCOPIC OUTCOMES

SUNDAY, MAY 7

8:45 – 9:00 AM
249. BIOSIMILAR INFliximab (CT-P13) IS NOT INFERIOR TO ORIGINATOR INFliximab: EXPLORATIVE IBD SUBGROUP-ANALYSES IN CROHN’S DISEASE AND ULCERATIVE COLITIS FROM THE NOR-SWITCH TRIAL

12:00 – 2:00 PM
SU1922. HISTOLOGICAL REMISSION IS PREDICTIVE OF IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OLE

TUESDAY, MAY 9

2:15 – 2:30 PM
1075. HYPERBARIC OXYGEN THERAPY IS SAFE AND EFFECTIVE FOR HOSPITALIZED ULCERATIVE COLITIS PATIENTS SUFFERING FROM MODERATE-SEVERE FLARES: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED TRIAL
FUNCTIONAL GI DISORDERS - DR. MARIA INES PINTO SANCHEZ

FUNCTIONAL DYSPEPSIA
SATURDAY, MAY 6

12:00 – 2:00 PM
SA1618. RANDOMIZED CONTROLLED TRIAL TO ASSESS THE EFFICACY & SAFETY OF CARAWAY OIL/L-MENTHOL PLUS USUAL CARE POLYPHARMACY VS. PLACEBO PLUS USUAL CARE POLYPHARMACY FOR FUNCTIONAL DYSPEPSIA

TUESDAY, MAY 9

12:00 – 2:00 PM
TU1674. MULTI-CENTER, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND, NON-INFERIORITY, PHASE 3 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF UI05MSPO15CT IN FUNCTIONAL DYSPEPSIA (MARS STUDY)

IRRITABLE BOWEL SYNDROME
SATURDAY, MAY 6

4:24 – 4:36 PM
S162. ANTIGLIADIN ANTIBODIES PREDICT THE SYMPTOMATIC RESPONSE TO GLUTEN-FREE DIET AND IMPROVEMENT IN GASTROINTESTINAL MOTILITY IN IBS PATIENTS

SUNDAY, MAY 7

9:15 – 9:30 AM
263. INTESTINAL, NON-INTESTINAL, AND EXTRA-DIGESTIVE RESPONSE TO LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION: RESULTS AT WEEK 4 PREDICT SUSTAINED RESPONSE

4:00 – 4:16 PM
430. FECAL MICROBIOTA TRANSPLANTATION IN IRRITABLE BOWEL SYNDROME AND A RANDOMIZED PLACEBO-CONTROLLED TRIAL

TUESDAY, MAY 9

12:00 – 2:00 PM
TU1612. IRRITABLE BOWEL SYNDROME PATIENT EXPERIENCE IN CANADA

UPPER GI DISORDERS - DR. DAVID ARMSTRONG

SUNDAY, MAY 7

4:15 – 4:30 PM
467. POOR ADHERENCE TO RECOMMENDATIONS TO PREVENT GASTROINTESTINAL BLEEDING AMONG ANTICOAGULATION CLINIC PATIENTS

MONDAY, MAY 8

8:30 – 8:45 AM
537. QUALITY OF ENDOSCOPIC SURVEILLANCE OF BARRETT’S ESOPHAGUS IN DENMARK

TUESDAY, MAY 9

10:36 – 10:54 AM
971: AGE OF HELICOBACTER PYLORI ERADICATION AND SUBSEQUENT RISK OF GASTRIC CANCER DEVELOPMENT: A POPULATION-BASED STUDY

4:00 – 4:15 PM
1118: BUDENOSIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PIVOTAL MULTICENTER TRIAL (EOS-1)